MPM
CORT icon

Meritage Portfolio Management’s Corcept Therapeutics CORT Stock Holding History

Meritage Portfolio Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$727K Sell
20,902
-2,505
-11% -$197K 0.05% 196
2025
Q3 		$1.95M Sell
23,407
-11,832
-34% -$856K 0.13% 162
2025
Q2 		$2.59M Sell
35,239
-1,200
-3% -$87K 0.16% 147
2025
Q1 		$4.16M Buy
36,439
+6,628
+22% +$403K 0.28% 108
2024
Q4 		$1.5M Buy
29,811
+2,783
+10% +$146K 0.09% 175
2024
Q3 		$1.25M Buy
27,028
+2,459
+10% +$87.4K 0.08% 189
2024
Q2 		$798K Buy
24,569
+119
+0.5% +$3.26K 0.05% 213
2024
Q1 		$616K Sell
24,450
-1,818
-7% -$43K 0.04% 228
2023
Q4 		$853K Buy
26,268
+949
+4% +$26.1K 0.06% 210
2023
Q3 		$690K Buy
25,319
+146
+0.6% +$4.23K 0.05% 214
2023
Q2 		$560K Buy
25,173
+5,585
+29% +$129K 0.04% 230
2023
Q1 		$424K Sell
19,588
-74
-0.4% -$1.62K 0.03% 223
2022
Q4 		$399K Buy
19,662
+607
+3% +$15.2K 0.03% 227
2022
Q3 		$489K Buy
19,055
+633
+3% +$16.9K 0.04% 212
2022
Q2 		$438K Sell
18,422
-456
-2% -$9.94K 0.03% 222
2022
Q1 		$425K Buy
18,878
+8,378
+80% +$178K 0.03% 231
2021
Q4 		$208K Buy
+10,500
New +$213K 0.01% 325

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Meritage Portfolio Management's CORT Position: Q4 2025 in Review

Meritage Portfolio Management reduced its Corcept Therapeutics (CORT) stake by 11% in Q4 2025, selling an estimated $197K and leaving 20,902 shares worth $727K. The position accounts for 0.05% of the portfolio, ranked #196.

Meritage Portfolio Management first reported a position in CORT in Q4 2021 and has held it in 17 quarters since. The position peaked at $4.16M in Q1 2025. 389 funds tracked by Wall St. Rank hold CORT as of Q4 2025.

  • Meritage Portfolio Management held 20,902 shares of Corcept Therapeutics worth $727K as of Q4 2025.
  • Meritage Portfolio Management sold 2,505 Corcept Therapeutics shares in Q4 2025, an estimated $197K.
  • Corcept Therapeutics made up 0.05% of Meritage Portfolio Management's portfolio in Q4 2025, its #196 holding.
  • Meritage Portfolio Management first reported a position in Corcept Therapeutics in Q4 2021 and has held it in 17 quarters since.
  • Meritage Portfolio Management's Corcept Therapeutics position peaked at $4.16M in Q1 2025.
  • 389 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2025.

Based on Meritage Portfolio Management's 13F filing for Q4 2025, filed 27 Jan 2026.